摘要化疗在晚期肺癌的治疗占有不可替代的地位，但恶性肿瘤化疗后骨髓抑制发生率高，粒细胞减少症是化疗最严重的血液学毒性反应，会影响化疗方案的正常进行，降低缓解率。聚乙二醇化重组人粒细胞刺激因子可用于预防及治疗粒细胞减少症，它是由重组人粒细胞集落刺激因子和单甲氧聚乙二醇共价结合后生成，其使用便利性、不良事件均优于重组人粒细胞集落刺激因子，但是存在应用时间短、应用经验不足、应用指征把握不准确等问题。本文系统阐述聚乙二醇化重组人粒细胞刺激因子的作用机制及应用进展。

abstractsChemotherapy has an irreplaceable position in the treatment of advanced lung cancer, but the incidence of myelosuppression after chemotherapy is high.The neutropenia is the most serious hematologic toxicity of chemotherapy, which will affect the normal progress of chemotherapy and reduce the remission rate.The PEGylated recombinant human granulocyte stimulating factor can be used for the prevention and treatment of neutropenia, which is formed by covalently combining recombinant human granulocyte colony stimulating factor and monomethoxypolyethyleneglycol, and is convenient to use and poor in use.The events were superior to recombinant human granulocyte colony-stimulating factor, but there were problems such as short application time, insufficient application experience, and inaccurate application indication.This article systematically describes the mechanism and application of PEGylated recombinant human granulocyte stimulating factor.